US20160237403A1 - Method of producing retinal pigment epithelial cell - Google Patents
Method of producing retinal pigment epithelial cell Download PDFInfo
- Publication number
- US20160237403A1 US20160237403A1 US15/028,076 US201415028076A US2016237403A1 US 20160237403 A1 US20160237403 A1 US 20160237403A1 US 201415028076 A US201415028076 A US 201415028076A US 2016237403 A1 US2016237403 A1 US 2016237403A1
- Authority
- US
- United States
- Prior art keywords
- cells
- laminin
- cell
- pigment epithelial
- retinal pigment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 title claims description 114
- 210000004027 cell Anatomy 0.000 claims abstract description 170
- 241000282414 Homo sapiens Species 0.000 claims abstract description 49
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 39
- 239000000758 substrate Substances 0.000 claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 208000017442 Retinal disease Diseases 0.000 claims abstract description 19
- 229940126585 therapeutic drug Drugs 0.000 claims abstract description 12
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 claims description 9
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 9
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 abstract description 64
- 230000006698 induction Effects 0.000 abstract description 54
- 238000011156 evaluation Methods 0.000 abstract description 13
- 238000012258 culturing Methods 0.000 abstract description 7
- 238000012136 culture method Methods 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 4
- 239000000790 retinal pigment Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 108010085895 Laminin Proteins 0.000 description 38
- 102000007547 Laminin Human genes 0.000 description 38
- 239000002609 medium Substances 0.000 description 38
- 108010038862 laminin 10 Proteins 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- 108010044426 integrins Proteins 0.000 description 21
- 102000006495 integrins Human genes 0.000 description 21
- 230000027455 binding Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 210000004694 pigment cell Anatomy 0.000 description 17
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 230000021164 cell adhesion Effects 0.000 description 15
- 238000012423 maintenance Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 108050003627 Wnt Proteins 0.000 description 9
- 102000013814 Wnt Human genes 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- OGKYMFFYOWUTKV-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(S(=O)(=O)NCCN)=CC=C(Cl)C2=C1 OGKYMFFYOWUTKV-UHFFFAOYSA-N 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 7
- 102000016387 Pancreatic elastase Human genes 0.000 description 7
- 108010067372 Pancreatic elastase Proteins 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000006727 cell loss Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- -1 microcarrier Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- DPDZHVCKYBCJHW-UHFFFAOYSA-N 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCCOC3=CC=2)=C(C=2N=CC=CC=2)N1 DPDZHVCKYBCJHW-UHFFFAOYSA-N 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 108050002823 Bestrophin Proteins 0.000 description 3
- 102000012304 Bestrophin Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 3
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 3
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 3
- 101150081664 PAX6 gene Proteins 0.000 description 3
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 3
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 102100038126 Tenascin Human genes 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 3
- 239000003590 rho kinase inhibitor Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102000018918 Activin Receptors Human genes 0.000 description 2
- 108010052946 Activin Receptors Proteins 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102100022794 Bestrophin-1 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 2
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 2
- 101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- DAQHMCWYXJEOCG-UHFFFAOYSA-N 2-oxopropanoic acid;sodium Chemical compound [Na].CC(=O)C(O)=O DAQHMCWYXJEOCG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102000008122 Casein Kinase I Human genes 0.000 description 1
- 108010049812 Casein Kinase I Proteins 0.000 description 1
- 229940122537 Casein kinase inhibitor Drugs 0.000 description 1
- 102100025745 Cerberus Human genes 0.000 description 1
- 101710010675 Cerberus Proteins 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 108010046591 human laminin-511 Proteins 0.000 description 1
- 102000007573 human laminin-511 Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 101150087532 mitF gene Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 210000001164 retinal progenitor cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Definitions
- the present invention relates to a method of efficiently producing retinal pigment epithelial (RPE) cells from human pluripotent stem cells, a method of stably culturing retinal pigment epithelial cells, and the like.
- RPE retinal pigment epithelial
- SFEB method As a method for producing retinal pigment epithelial cells from pluripotent stem cells, a method called SFEB method including culturing ES cells as a floating aggregate in a serum-free medium (patent document 1 etc.), a method including inducing differentiation of pluripotent stem cells in the presence of a differentiation-inducing factor on a culture substrate coated with a weakly cell adhesive coating agent and the like (non-patent document 1 etc.) are known.
- laminin is being preferably used and, for example, non-patent document 2 reports successful maintenance culture of human ES cell on laminin-511 for a long term.
- E8 fragment known as an altered laminin having an improved cell adhesion activity
- patent document 2 and non-patent document 3 disclose culture methods of human pluripotent stem cells, which use E8 fragment of human laminin- ⁇ 5 ⁇ 1 ⁇ 1 (laminin-511E8, hereinafter indicated in the same manner) and human laminin-322E8.
- Non-patent document 4 describes that laminin-511E8 maintains binding activity to ⁇ 6 ⁇ 1 integrin, which is of the same level as that of full-length laminin-511, and patent document 2 describes that, by using said laminin-511E8, pluripotent stem cells can be stably immobilized on a culture dish, as a result of which the cells, while maintaining differentiation pluripotency, can be subjected to maintenance culture.
- no report has documented utilization of such E8 fragment of laminin for other than culture of pluripotent stem cells, for example, differentiation induction of pluripotent stem cells and the like.
- non-patent document 5 describes that the differentiation induction efficiency into retinal pigment epithelial cells markedly increased by adhesion culture of pluripotent stem cells on laminin-111 and Matrigel.
- no report has documented use of the E8 fragment of laminin for the induction of differentiation of pluripotent stem cell into retinal pigment epithelial cell.
- An object of the present invention is to provide a production method of retinal pigment epithelial cell that improves differentiation induction efficiency of pluripotent stem cell into retinal pigment epithelial cell, and can provide highly pure retinal pigment epithelial cell by a simple and easy operation in a short period, a culture method of retinal pigment epithelial cell that can stably grow and culture a cell, a toxicity/efficacy evaluation method using a retinal pigment epithelial cell useful for transplantation therapy, and a therapeutic drug for a retinal disease.
- the present inventors have conducted intensive studies in an attempt to achieve the above-mentioned objects and found that, when human pluripotent stem cells are cultured on a culture substrate coated with laminin-E8, the seeded pluripotent stem cells rapidly adhere to the culture substrate, a large amount of pigment cell is generated from early stages, the yield of retinal pigment epithelial cells can be markedly improved, cells are not easily lost during medium exchange, the purification step can be simplified, and a highly pure cell population can be obtained in a short period.
- the operability and economic efficiency which are the problems in inducing differentiation of pluripotent stem cells into retinal pigment epithelial cells, can be markedly improved, and the retinal pigment epithelial cells of interest can be produced stably and efficiently, which resulted in the completion of the present invention.
- the present invention relates to the following.
- a production method of retinal pigment epithelial cells comprising a step of adhesion culture of human pluripotent stem cells on a culture substrate coated with a laminin-E8 fragment.
- the method of [1] or [2], wherein the step of adhesion culture is performed in the presence of a differentiation-inducing factor.
- the method of any of [1]-[3], wherein the human pluripotent stem cells are human iPS cells.
- a retinal pigment epithelial cell sheet produced by adhesion culture of human pluripotent stem cells on a culture substrate coated with a laminin-E8 fragment.
- An amplification method of retinal pigment epithelial cells comprising a step of adhesion culture of retinal pigment epithelial cells on a culture substrate coated with a laminin-E8 fragment.
- a purification method of retinal pigment epithelial cells comprising a step of adhesion culture of retinal pigment epithelial cells on a culture substrate coated with a laminin-E8 fragment.
- a therapeutic drug for a retinal disease comprising retinal pigment epithelial cells produced by the method of any of [1]-[4], or retinal pigment epithelial cells cultured by the method of [7].
- retinal pigment epithelial cells can be produced in a high yield from pluripotent stem cells.
- differentiation induction efficiency is improved, and a cell population containing retinal pigment epithelial cells at a high concentration can be obtained, and highly pure retinal pigment epithelial cells can be produced by a simple and easy purification operation.
- retinal pigment epithelial cells can be stably adhered, the cells are not easily lost during medium exchange, and can be stably passaged.
- FIG. 1 is a schematic showing of the structure of laminin-E8.
- FIG. 2 shows expression of RPE-related genes by RPE cells induced from human iPS cells (201B7).
- FIG. 3 shows the cell adhesion state on days 1, 2 and 3 after the start of differentiation induction of iPS cells seeded on a substrate coated with laminin-511 E8, Matrigel or laminin-511 full-length in Comparative Example 3.
- FIG. 4 shows cell populations on days 15 and 40 after the start of differentiation induction of iPS cells seeded on a substrate coated with laminin-511 E8, Matrigel or laminin-511 full-length in Comparative Example 3.
- the present invention is a production method of retinal pigment epithelial cells, comprising a step of adhesion culture of human pluripotent stem cells by using a culture substrate coated with a laminin-E8 fragment (hereinafter to be referred to as “the production method of the present invention”).
- the “pluripotent stem cell” in the present invention means a stem cell having self-replication competence and differentiation pluripotency, and is not particularly limited.
- embryonic stem cells ES cell
- iPS cell induced pluripotent stem cells
- human ES cells or human iPS cells are utilized and, more preferably, human iPS cells are utilized.
- the “iPS cell” in the present invention means a cell that artificially acquired self-replication competence and differentiation pluripotency by contacting a nuclear reprogramming factor with somatic cells (e.g., fibroblast, skin cell, lymphocyte etc.).
- somatic cells e.g., fibroblast, skin cell, lymphocyte etc.
- the production method of iPS cells in the present invention is not particularly limited.
- the “retinal pigment epithelial cell” in the present invention refers to an epithelial cell constituting the retinal pigment epithelium, and a progenitor cell thereof. Whether a retinal pigment epithelial cell or not can be confirmed by, for example, expression of cell markers (RPE65, CRALBP, MERTK, BEST1 etc.), cell forms (intracellular melanin dye deposition, polygonal and flat cell form, formation of polygonal actin bundle etc.) and the like.
- cell markers RPE65, CRALBP, MERTK, BEST1 etc.
- cell forms intracellular melanin dye deposition, polygonal and flat cell form, formation of polygonal actin bundle etc.
- the progenitor cell of retinal pigment epithelial cell means a cell directed to be induced to differentiate into retinal cell, and whether a progenitor cell or not can be confirmed by expression of cell markers (Mitf, Pax6, Rx, Crx etc.) and the like.
- Functional evaluation of retinal pigment epithelial cell can be confirmed using, for example, secretability, phagocytic capacity and the like of cytokine (VEGF, PEDF etc.) as an index.
- laminin in the present invention is a heterotrimer molecule consisting of ⁇ , ⁇ , ⁇ chains, and is an extracellular matrix protein containing isoforms having different subunit chain compositions. Specifically, laminin has about 15 kinds of isoforms including heterotrimers of combinations of 5 kinds of ⁇ chain, 4 kinds of ⁇ chain and 3 kinds of ⁇ chain. The number of each of ⁇ chain ( ⁇ 1- ⁇ 5), ⁇ chain ( ⁇ 1- ⁇ 4) and ⁇ chain ( ⁇ 1- ⁇ 3) is combined to determine the name of laminin.
- a laminin composed of a combination of al chain, ⁇ 1 chain, ⁇ 1 chain is named laminin-111
- a laminin composed of a combination of ⁇ 5 chain, ⁇ 1 chain, ⁇ 1 chain is named laminin-511
- a laminin composed of a combination of ⁇ 5 chain, ⁇ 2 chain, ⁇ 1 chain is named laminin-521.
- laminin for example, a laminin derived from a mammal can be used. Examples of the mammal include mouse, rat, guinea pig, hamster, rabbit, cat, dog, sheep, swine, bovine, horse, goat, monkey and human.
- Human laminin is preferably used when retinal pigment epithelial cells are produced for the purpose of transplanting to human, and the like. At the present stage, human laminin is known to include 15 kinds of isoforms.
- Laminin-E8 fragment was originally one of the fragments obtained by digesting mouse laminin-111 with elastase, and identified as a fragment having strong cell adhesion activity (EMBO J., 3:1463-1468, 1984, J. Cell Biol., 105:589-598, 1987).
- EMBO J. 3:1463-1468, 1984, J. Cell Biol., 105:589-598, 1987.
- the presence of a fragment corresponding to the E8 fragment of mouse laminin-111 is assumed in laminin other than mouse laminin-111.
- separation and identification of E8 fragment by digestion of laminin other than mouse laminin-111 with elastase has not been reported heretofore.
- laminin-E8 fragment to be used in the present invention is not required to be an elastase digestion product of each laminin, but may be a recombinant as long as it is a fragment of laminin having a cell adhesion activity similar to that of each corresponding laminin and having a structure corresponding to that of E8 fragment digested with elastase. That is, the “laminin-E8 fragment (hereinafter sometimes to be indicated as “laminin-E8”)” in the present invention refers to a molecule constituting a heterotrimer in each C-terminal region of ⁇ chain, ⁇ chain and ⁇ chain, maintaining a binding activity to integrin, as well as maintaining a cell adhesion activity. Laminin-E8 shows integrin binding specificity that varies for each laminin isoform, and can exert a strong adhesion activity to a cell that expresses the corresponding integrin.
- laminin-E8 in the present invention is a laminin fragment having,
- Examples of the laminin-E8 in the present invention include a molecule showing binding specificity to at least one of the integrins expressed on the surface of human pluripotent stem cell and/or human retinal pigment epithelial cell, preferably, a molecule showing binding specificity to an integrin expressed on the surface of both human pluripotent stem cells and human retinal pigment epithelial cells, and an integrin expressed on the surface of human retinal pigment epithelial cells are preferably used.
- Examples of the integrin expressed on the surface of human pluripotent stem cell include ⁇ 6 ⁇ 1 integrin and the like, and examples of the integrin expressed on the surface of human retinal pigment epithelial cell include ⁇ 6 ⁇ 1 integrin, ⁇ 3 ⁇ 1 integrin, ⁇ 7 ⁇ 1 integrin and the like.
- Laminin-E8 in the present invention shows binding specificity to integrin at least equivalent to each laminin.
- Laminin-E8 showing particularly strong affinity to integrin is preferably used.
- “Laminin-E8 showing particularly strong affinity to integrin” is one showing a significantly low dissociation constant as measured by a known method and, for example, the dissociation constant measured by, for example, the method shown in Table 1 of The Journal of Biological Chemistry (2009) 284, pp. 7820-7831 is not more than 10 nM.
- laminin-E8 in the present invention one having a strong cell adhesion activity is preferably used.
- the “laminin-E8 having a strong cell adhesion activity” is one showing a significantly strong adhesion activity in a cell adhesion test with measurement by a known method and shows an adherent cell number of not less than 400 cells/mm 2 at a coating concentration of laminin-E8 of not more than 10 nM when, for example, the cell adhesion assay described in The Journal of Biological Chemistry (2007) 282, pp. 11144-11154 is performed.
- laminin-E8 one showing binding specificity to ⁇ 6 ⁇ 1 integrin, capable of stably adhering pluripotent stem cells in the initial stage of differentiation induction, and capable of stably adhering retinal pigment epithelial cells in the latter stage of differentiation induction or progenitor cells thereof is preferably used.
- laminin-511 E8 is highly preferable among laminin-E8, since it has binding specificity to ⁇ 3 ⁇ 1 integrin and ⁇ 7 ⁇ 1 integrin in addition to ⁇ 6 ⁇ 1 integrin, and can contribute to the improvement of differentiation induction efficiency of pluripotent stem cells into retinal pigment epithelial cells, or stabilization of maintenance culture of retinal pigment epithelial cells, by improving the adhesion activity to retinal pigment epithelial cells.
- the laminin-E8 in the present invention is, as mentioned above or shown in FIG. 1 , a laminin fragment structurally corresponding to a fragment having a cell adhesion activity (E8 fragment) in an elastase digestion product of mouse laminin-111. That is, it maintains a part of domain II (triple-stranded coiled-coil domain) of full-length laminin (E8 fragment depicted in FIG. 1 does not show such manner but actually maintains a coiled-coil structure), and forms a short coiled-coil structure on the N terminal side of E8 with a corresponding fragment of ⁇ chain and a corresponding fragment of ⁇ chain.
- the G1-G3 domain structure of ⁇ chain is maintained.
- the ⁇ chain and ⁇ chain are bonded to each other by forming a disulfide bond via a cysteine residue on each C-terminal side.
- laminin-E8 in the present invention may be an enzyme-treated product obtained by treating natural laminin with elastase, or a recombinant produced by gene recombination.
- a tag may be bonded to the N terminal for the purpose of purification and the like as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and the cell adhesiveness is not impaired.
- tag is not particularly limited and, for example, His tag, Flag tag, HA tag and the like can be mentioned.
- the sequence of the linker region between the tag and laminin-E8 is not particularly limited as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and cell adhesiveness is not impaired.
- a part of the amino acid sequence may be deleted, added, or substituted as long as the binding activity of the corresponding laminin to integrin is maintained, and the cell adhesiveness thereof is not impaired.
- the G4, G5 domains may be partly or entirely contained in the laminin-E8 in the present invention as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and cell adhesiveness thereof is not impaired.
- the G4, G5 domains may be partly or entirely contained in the laminin-511 E8 as long as the binding activity to integrin ⁇ 6 ⁇ 1 of the equivalent level as laminin-511 is maintained, and the cell adhesion activity is not impaired.
- ⁇ chain and ⁇ chain of laminin-E8 are bonded via cysteine on the C-terminal side of the coiled-coil part. Since the cysteine influences the integrin binding activity, it is desirably not substituted or deleted. Furthermore, since the C-terminal side amino acid following said cysteine in the ⁇ chain also influences the integrin binding activity, it is desirably at least not deleted (J Biol Chem. 2007 Apr. 13; 282(15):11144-54).
- laminin-E8 examples include rhLM511E8 produced in Example (3) of WO 2011/043405. Said laminin-511E8 can be preferably utilized as the laminin-E8 in the present invention.
- the “culture substrate” to be used in the present invention can be produced by coating a surface of an incubator with the laminin-E8 in the present invention.
- “coating” a surface of an incubator means adsorption of laminin-E8 to the surface of the incubator by some interaction between laminin-E8 and the incubator surface, where the orientation of the laminin-E8 does not pose a particular problem in affording the effect of the present invention.
- the incubator is not particularly limited as long as it can be used for cell culture and, for example, dish (also referred to as culture dish), petri dish and plate (microtiter plate, microplate, deep well plate etc.
- the culture substrate in the present invention may be applied with an appropriate surface treatment as long as the cell adhesion property by laminin-E8 is not impaired.
- the “adhesion culture” in the present invention means culture in a state where the cells of interest are adhered to the bottom of the incubator via laminin-E8, and do not float in the culture medium even when the incubator is gently shaken during culture. Since laminin-E8 to be used in the present invention shows extremely superior cell adhesiveness, the cells after cell seeding are preferably uniformly dispersed by a method including rapidly trembling the incubator and the like.
- the cells of interest may be subjected to floating culture in an incubator containing laminin-E8 before and after the adhesion culture, as long as the object of the present invention can be achieved.
- the medium is constituted of a basal medium, a serum and/or a serum replacement, and other components.
- a basal medium one or plural kinds of synthetic media generally used for culturing mammalian cells can be used in combination and, for example, commercially available products such as DMEM, GMEM and the like can be obtained.
- the serum As the serum, a serum derived from a mammal such as bovine, human and the like can be used.
- the serum replacement is a low-protein replacement that replaces serum such as FBS and the like used for the cell culture, and commercially available products such as Knockout Serum Replacement (KSR), Chemically-defined Lipid concentrated (manufactured by Gibco), Glutamax (manufactured by Gibco) and the like, as well as N2, B27 and the like which are serum replacements for nerve cell culture can be obtained.
- KSR Knockout Serum Replacement
- Chemically-defined Lipid concentrated manufactured by Gibco
- Glutamax manufactured by Gibco
- N2 B27 and the like which are serum replacements for nerve cell culture
- a serum replacement is preferable, and KSR is particularly preferable from the aspect of quality management of the cell of interest.
- the concentration of serum or serum replacement can be appropriately set within the range of, for example, 0.5-30% (v/v).
- the concentration may be constant, or gradually changed.
- the concentration may be lowered in stages at intervals of about 1-3 days (preferably 2 days).
- serum or serum replacement can be added at 3 stages of concentration of 20%, 15% and 10%.
- a Rho kinase inhibitor such as Y-27632 and the like can be used to suppress cell death of human pluripotent stem cells dispersed in a culture medium.
- a Rho kinase inhibitor may be added in the period of a part or the whole period of the differentiation induction step. For example, unnecessary cells that did not differentiate into the cell of interest can be removed by cell death by using a medium free of a Rho kinase inhibitor in the latter period of the differentiation induction step.
- the medium can contain other components generally used for culturing mammalian cells, besides those mentioned above.
- the concentration of human pluripotent stem cells to be used in the production method of the present invention is not particularly limited as long as pluripotent stem cells can be uniformly seeded, and adhesion culture is possible.
- a 10 cm dish it is 1 ⁇ 10 5 -1 ⁇ 10 8 cells, preferably 2 ⁇ 10 6 -5 ⁇ 10 7 cells, more preferably 5 ⁇ 10 5 -9 ⁇ 10 6 cells, per 1 dish.
- the adhesion culture in the production method of the present invention can also be performed in the presence of a differentiation-inducing factor.
- a differentiation-inducing factor a factor known as a factor promoting differentiation induction into the cell of interest can be utilized. Since the production method of the present invention includes differentiation induction into retinal pigment epithelial cells, a differentiation-inducing factor into retinal pigment epithelial cells is desirably used. Examples of the differentiation-inducing factor into retinal pigment epithelial cells include Nodal signal inhibitor, Wnt signal inhibitor, Sonic hedgehog signal inhibitor, and Activin signal promoter and the like.
- the Nodal signal inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Nodal, and protein, nucleic acid, low-molecular-weight compound and the like can be used.
- the Nodal signal inhibitor include protein, peptide or nucleic acid such as Lefty-A, soluble Nodal receptor, anti-Nodal antibody, Nodal receptor inhibitor and the like; low-molecular-weight compound such as SB-431542 and the like, and the like.
- a low-molecular-weight compound such as SB-431542 and the like which is easily available and shows less difference between lots is preferable.
- the Wnt signal inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Wnt, and protein, nucleic acid, low-molecular-weight compound and the like can be used.
- the Wnt signal inhibitor include protein, peptide or nucleic acid such as Dkkl, Cerberus protein, Wnt receptor inhibitor, soluble Wnt receptor, Wnt antibody, casein kinase inhibitor, dominant negative Wnt protein and the like; and low-molecular-weight compound such as CKI-7 (N-(2-aminoethyl)-5-chloro-isoquinoline-8-sulfonamide), D4476 (4- ⁇ 4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl ⁇ benzamide), IWR-1-endo(IWR1e), IWP-2 and the like.
- a low-molecular-weight compound which is easily available and shows less difference between lots is preferable.
- a low-molecular-weight compound having an activity to selectively inhibit casein kinase I is preferable and, for example, CKI-7, D4476 and the like can be utilized.
- Activin signal promoter examples include protein belonging to the Activin family, Activin receptor, Activin receptor agonist and the like.
- the concentration of these differentiation-inducing factors can be appropriately selected according to the kind of the differentiation-inducing factor. Specifically, when SB-431542 is used as a Nodal signal inhibitor, the concentration is, for example, 0.01-50 ⁇ M, preferably 0.1-10 ⁇ M, more preferably 5 ⁇ M; when CKI-7 is used as a Wnt signal inhibitor, it is added at the concentration of 0.01-30 ⁇ M, preferably 0.1-30 ⁇ M, more preferably 3 ⁇ M.
- a combination of a Nodal signal inhibitor (e.g., SB-431542) and a Wnt signal inhibitor (e.g., CKI-7) is preferably used as a differentiation-inducing factor.
- Culture according to the aforementioned method induces differentiation of pluripotent stem cells into retinal pigment epithelial cells, whereby retinal pigment epithelial cells can be generated generally on day 25-45 from the seeding of pluripotent stem cells.
- Generation of retinal pigment epithelial cell can be confirmed according to the aforementioned method.
- the medium is exchanged with a maintenance medium for retinal pigment epithelial cells and, for example, the cells are preferably further cultured for 5-10 days while exchanging the total amount of medium at a frequency of not less than once in 3 days.
- a melanin dye deposition cell population and a polygonal flat cell population adhered to the basal lamina can be observed more clearly.
- the maintenance medium for retinal pigment epithelial cells for example, those described in IOVS, March 2004, Vol. 45, No. 3, Masatoshi Haruta, et. al., IOVS, November 2011, Vol. 52, No. 12, Okamoto and Takahashi, J. Cell Science 122 (17), Fumitaka Osakada, et. al., IOVS, February 2008, Vol. 49, No. 2, Gamm, et. al. can be used, which are constituted of a basal medium, a serum and/or a serum replacement, and other components.
- the basal medium one or plural kinds of synthetic media generally used for culturing mammalian cells can be used in combination and, for example, commercially available products such as DMEM, GMEM and the like can be obtained.
- the serum As the serum, a serum derived from a mammal such as bovine, human, swine and the like can be used.
- the serum replacement is a low-protein replacement that replaces serum such as FBS and the like used for the cell culture, and commercially available products such as Knockout Serum Replacement (KSR), Chemically-defined Lipid concentrated (manufactured by Gibco), Glutamax (manufactured by Gibco) and the like, as well as N2, B27 and the like which are serum replacements for nerve cell culture can be obtained.
- KSR Knockout Serum Replacement
- Chemically-defined Lipid concentrated manufactured by Gibco
- Glutamax manufactured by Gibco
- B27 is particularly preferable from the aspect of quality management of the cell of interest.
- Examples of other components include L-glutamine, penicillin sodium, sulfuric acid streptomycin and the like.
- the production method of the present invention may further contain a step of purifying retinal pigment epithelial cells by a concentration operation. Since the production method of the present invention markedly improves the differentiation induction efficiency, a highly pure retinal pigment epithelial cell can be obtained in a short production period by a simple and easy operation.
- a method of concentrating retinal pigment epithelial cells is not particularly limited as long as it is generally known as a method of concentrating cells and, for example, methods such as filtration, centrifugation, perfusion separation, flow cytometry separation, trap separation by antibody immobilized carrier and the like can be used. Preferably, a method such as filtration using nylon mesh and the like can be utilized.
- human pluripotent stem cells can be rapidly adhered to an incubator via laminin-E8 superior in cell adhesion, and culture in an immobilized state markedly improves differentiation induction efficiency and, moreover, cell loss during medium exchange can be suppressed. Therefore, cell population of retinal pigment epithelial cells at a high concentration can be obtained in a large amount. Furthermore, cell purification can be performed by a simple and easy operation, the time necessary for a purification step can be shortened, and retinal pigment epithelial cells can be produced extremely efficiently. In addition, according to the production method of the present invention, retinal pigment epithelial cells can be adhered to each other to form a sheet-like structure.
- a sheet of retinal pigment epithelial cells can be produced by the production method of the present invention.
- the sheet of retinal pigment epithelial cells is useful as a cell population to be used as a cell transplantation therapeutic drug for the treatment of retinal diseases, as described in detail below in 3.
- the present invention also relates to an amplification method of retinal pigment epithelial cells, comprising a step of adhesion culture of retinal pigment epithelial cells by using a culture substrate coated with laminin-E8 (hereinafter to be referred to as “the amplification method of the present invention”).
- the amplification method of the present invention retinal pigment epithelial cells can be easily grown by a convenient method.
- retinal pigment epithelial cells derived from a mammal can be used as the retinal pigment epithelial cell in the amplification method of the present invention.
- the mammal include mouse, rat, guinea pig, hamster, rabbit, cat, dog, sheep, swine, bovine, horse, goat, monkey and human.
- Human retinal pigment epithelial cell is preferably used when retinal pigment epithelial cells are produced for the purpose of transplanting to human, and the like.
- the retinal pigment epithelial cell in the amplification method of the present invention refers to epithelial cells constituting retinal pigment epithelium, and progenitor cells thereof. Examples thereof include retinal pigment epithelial cell derived from a living organism; retinal pigment epithelial cell induced to differentiate from an undifferentiated cell (pluripotent stem cell, precursor of retinal pigment epithelial cell etc.); retinal pigment epithelial cell transdifferentiated from a differentiated cell or a precursor of a cell other than retinal pigment epithelial cell etc., preferably a retinal pigment epithelial cell induced to differentiate from an undifferentiated cell, more preferably a retinal pigment epithelial cell induced to differentiate from a pluripotent stem cell, which is obtained by the above-mentioned production method of the present invention.
- the concentration of the retinal pigment epithelial cells used for the amplification method of the present invention is not particularly limited as long as uniform adhesion culture of retinal pigment epithelial cells is possible.
- concentration of the retinal pigment epithelial cells used for the amplification method of the present invention is not particularly limited as long as uniform adhesion culture of retinal pigment epithelial cells is possible.
- a 10 cm dish it is 1 ⁇ 10 5 -1 ⁇ 10 8 cells, preferably 2 ⁇ 10 6 -5 ⁇ 10 7 cells, more preferably 5 ⁇ 10 5 -1 ⁇ 10 7 cells, per 1 dish.
- the laminin-E8 fragment in the amplification method of the present invention is similar to that mentioned above, and a coating method of a culture substrate is also similar. Therefore, by culturing the retinal pigment epithelial cells obtained by the above-mentioned production method of the present invention on the same incubator coated with the laminin-E8 fragment, the obtained retinal pigment epithelial cells can be directly amplified in situ and can be obtained in large amounts. According to the amplification method of the present invention, moreover, the cells contained in the differentiation-induced retinal pigment epithelial cells, which could not be induced to differentiate can be relatively reduced. Therefore, the amplification method of the present invention can also be used as a purification method of retinal pigment epithelial cells.
- laminin-E8 As the laminin-E8 to be used in the amplification method of the present invention, particularly, laminin-511 E8 is preferable among laminin-E8, since it has binding specificity to ⁇ 3 ⁇ 1 integrin and ⁇ 7 ⁇ 1 integrin in addition to ⁇ 6 ⁇ 1 integrin, and can contribute to the stabilization of maintenance culture of retinal pigment epithelial cells and cell proliferation, by improving the adhesion activity to retinal pigment epithelial cells.
- a membranous retinal pigment epithelial cell group can also be utilized directly or after recovery by separation from the culture substrate, as a therapeutic drug for retinal diseases shown below.
- the retinal pigment epithelial cells obtained by the production method or amplification method of the present invention are cultured on laminin-E8, particularly laminin-511 E8. Therefore, they can be easily recovered by separation from the culture substrate singly as cells, or as a sheet, and have superior property.
- the retinal pigment epithelial cells produced by the production method of the present invention, and the retinal pigment epithelial cells amplification by the amplification method of the present invention can be used as a cell transplantation therapeutic drug to be transplanted in the form of a suspension or sheet to living organisms for the treatment of retinal diseases.
- Retinal disease is an ophthalmic disease relating to the retina and also includes complications with other diseases such as diabetes and the like.
- the retinal pigment epithelial cells produced by the production method of the present invention can be utilized as a normal or disease model cell for screening for therapeutic drugs for retinal diseases and therapeutic drug for diseases of other complications such as efficacy evaluation diabetes and the like, or prophylactic drug thereof, safety test of chemical substances and the like, stress test, toxicity test, side effect test, infection/contamination test. On the other hand, they can also be utilized for toxicity study, toxicity test and the like of phototoxicity unique to retinal cells, retinal excitotoxicity and the like.
- the evaluation method thereof includes stimulation, toxicity tests such as apoptosis evaluation and the like, as well as tests for evaluation of influence on normal differentiation from progenitor cell into retinal pigment epithelial cell and visual cell (expressed protein analysis and phagocytic capacity test by RT-PCR of various gene markers, ELISA of cytokine and the like), toxicity test of phototoxicity and the like, retinal electric potential and transepithelial impedance on visual function, cell injury test caused by autoimmune reaction and the like.
- a cell material for these tests not only retinal pigment epithelial cells but also progenitor cells thereof can be used and, for example, a plate on which cells are adhered by seeding, a cell suspension, a sheet or compact thereof can be provided. They can be used as an extrapolation test of human and animal tests.
- iPS cells 112007, provided by Kyoto University
- human peripheral blood mononuclear cell
- the laminin-coated culture dish was produced by coating a 9 cm culture dish (BD FALCON) with a 0.5 ⁇ g/cm 2 aqueous solution of laminin-511 E8 fragment (protein disclosed in Example (3) of WO 2011043405. (manufactured by Nippi (iMatrix-511, NIP-8920-02))) at 37° C. for not less than 1 hr. iPS cells rapidly adhered on the culture dish, and formation of floating aggregate was not confirmed.
- the above-mentioned differentiation induction was performed according to the following timeline, and differentiation induction in the Examples and Comparative Examples in the present specification followed this timeline.
- the primary differentiation induction medium (20% KSR) was used for Day 1-4
- the secondary differentiation induction medium (15% KSR) was used for Day 5-8
- the tertiary differentiation induction medium (10% KSR) was used for Day 9-12
- the quaternary differentiation induction medium (10% KSR) was used from Day 13 to around Day 40 when pigment cells are confirmed.
- laminin-511 E8 fragment as a coating agent, seeded iPS cells rapidly adhered to the culture dish at a high density, and stably maintained an adhesion state even during culture period in a differentiation induction medium. Therefore, the cell loss could be suppressed low even when the total amount of medium was repeatedly exchanged. Furthermore, the rate of generation of pigment cells was drastically improved and the differentiation induction efficiency was markedly improved as compared to when the iPS cells were seeded on an incubator coated with collagen.
- the cell population containing pigment cells on Day 47 which underwent adhesion culture in the culture dish in Example 1 and Example 2, was treated with 0.01% Trypsin-0.53 mM EDTA and cell aggregates were detached from the culture dish. Then, adhesion between the cells was detached by mild pipetting. Protease liquid and residual impurities thereof in the cell mixture were removed together with the supernatant by centrifugation, then, unnecessary cells were separated by filtration separation through a cell strainer (DB Falcon Cell Strainer 40 ⁇ m Nylon), and a cell population containing RPE cells was recovered (Day 48).
- DB Falcon Cell Strainer 40 ⁇ m Nylon DB Falcon Cell Strainer 40 ⁇ m Nylon
- the obtained cells were seeded in RPE maintenance medium described in Example 1 in the same 5 culture dishes coated with laminin-511 E8 as in Example 1 at 9 ⁇ 10 6 cells/9 cm dish, and standing culture was performed until around Day 50 when adhesion of the RPE cell colony was confirmed.
- the total amount of the medium was exchanged with RPE maintenance medium not less than once in 3 days for 3 weeks, then subjected to filtration separation using a filter, seeded in each of the same 5 culture dishes coated with laminin-511 E8, and similarly cultured for 2 weeks.
- retinal pigment epithelial cells were amplified to the yield of 25 dishes (10 cm dish) from any cell populations of Example 1 and Example 2.
- the purity calculation data of a dish with 98.6% purity is shown.
- Example 2 By a method similar to that of Example 1 except that, in the differentiation induction step of Example 1, floating culture was performed using a non-adhesive culture dish (Nunc) treated with MPC (2-methacryloxylethyl phosphoryl choline) instead of adhesion culture using a culture dish coated with laminin-511 E8 (BD FALCON), a differentiation induction step was performed.
- Nunc non-adhesive culture dish
- MPC 2-methacryloxylethyl phosphoryl choline
- the adhesiveness of the cell to the poly-D lysine/gelatin-coated culture dish was weak as compared to the laminin-511 E8-coated culture dish, and the cells were easily lost during medium exchange. Therefore, the rate of the pigment cells on Day 47 after the start of the culture was not more than 1/20 of Example 1 by visual observation of the number of pigment cells relative to the total cells in the culture dish, and differentiation induction efficiency was also markedly low.
- the pigment cells obtained in Examples 1-3 were subjected to RT-PCR analysis using primers having the following sequences, according to the method described in Journal of Cell Science 2009 Sep. 1 122 3169-79.
- RPE cell specific genes RPE65, CRALBP, MERTK, BEST1
- RPE65-F (SEQ ID NO: 1) TCC CCA ATA CAA CTG CCA CT RPE65-R (SEQ ID NO: 2) CCT TGG CAT TCA GAA TCA GG CRALBP-F (SEQ ID NO: 3) GAG GGT GCA AGA GAA GGA CA CRALBP-R (SEQ ID NO: 4) TGC AGA AGC CAT TGA TTT GA MERTK-F (SEQ ID NO: 5) TCC TTG GCC ATC AGA AAA AG MERTK-R (SEQ ID NO: 6) CAT TTG GGT GGC TGA AGT CT BEST1-F (SEQ ID NO: 7) TAG AAC CAT CAG CGC CGT C BEST1-R (SEQ ID NO: 8) TGA GTG TAG TGT GTA TGT TGG
- the pigment cells obtained in Examples 1-3 were detected for the production amount of PEDF by ELISA according to the method described in IOVS. 2006 47 612-3624. As a result, it was confirmed that they similarly had cytokine secretional capacity like the RPE cells of adult retina (Table 2).
- Example 2 TABLE 2 PEDF secretion amount days concentration (ng/mL) after standard passage
- Example 1 Example 2
- Example 3 mean error 7 945.2 998.8 993.3 979.1 17.0 10 1266.1 1263.1 1288.0 1272.4 7.9 12 1574.3 1567.0 1616.3 1585.8 15.4 14 1542.0 1622.4 1524.3 1562.9 30.2 17 1621.2 1533.5 1482.9 1545.8 40.4 19 1727.7 1752.7 1842.8 1774.4 35.0 21 1504.8 1581.0 1570.6 1552.1 23.8
- the pigment cells obtained in Examples 1-3 were analyzed for the phagocytic capacity according to the method described in J Cell Sci. 1993 104 37-49, and using FluoSpheres (registered trade mark) fluorescence microsphere (Invitrogen, F13081). As a result, it was confirmed that the cells had phagocytic capacity of the same level as commercially available human RPE cell line.
- This Example afforded similar results even when iPS cells of a different line (201B7) were used.
- similar results were obtained even when the phagocytic capacity was analyzed using iPS cells of a different line (201B7) and pHrod Green E. coli BioParticles (registered trade mark) Conjugate for Phagocytosisb (Molecular Probes, P35366), according to the method described in The Lancet 2012 379 713-720.
- Example 2 By a method similar to that in Example 1 and using iPS cells (201B7, provided by Kyoto University) derived from human skin (fibroblast) in the same manner as in Example 2 and a culture dish coated with any of the following 1)-3), differentiation induction was performed. A test including simultaneously subjecting 3 substrates to differentiation induction was performed twice, and a supplemental test was performed once for each substrate.
- Laminin-511 E8 (molecular weight 150,000) (iMatrix511: manufactured by Nippi, NIP-8920-02) was used for coating at 0.5 ⁇ g/cm 2 .
- Human recombinant laminin-511 full-length (molecular weigh t 776,000) (sold by: VERITAS Corporation (produced by: BioLamina)/BLA-LN511) was used for coating at 2.59 ⁇ g/cm 2 .
- Matrigel manufactured by BD, 354230 (total protein concentration: 9-12 mg/ml)
- basal lamina matrix, soluble basal lamina preparation derived from mouse Engelbreth-Holm-Swarm (EHS) sarcoma, containing major molecules of basal lamina, type IV collagen, nidogen, perlecan, laminin-111 is dissolved overnight at 4° C., and used in the cold state for coating a culture container at 10 mL/57 cm 2 (0.175 ml/cm 2 ).
- the state of cell adhesion on day 1, day 2 and day 3 from the start of differentiation induction is shown in FIG. 3 .
- a laminin-511 E8-coated substrate from the next day of seeding, the cells grew while uniformly adhering to the whole surface of the dish, and rapidly entered the differentiation induction process.
- a matrigel (laminin-111)-coated substrate cell adhesion was inconsistent, with a part invading into the gel, and eventually failed to form a whole surface layer.
- adhesion was weak and the cells partly formed a colony on the next day of seeding. It took 4-5 days for the cells to grow and spread over the entire surface of the dish. Therefore, the differentiation induction process became uneven to leave a part where differentiation induction did not proceed.
- FIG. 4 The state of cell population on day 15 from the start of differentiation induction and before the filtration separation step of the cells (around day 40) is shown in FIG. 4 .
- a laminin-511 E8-coated substrate cells were spread on the entire surface around day 15, layered cells were accumulated thick, and melanin color development was observed.
- Around day 40 cells were layered uniformly and thick, and breakage or delamination of the basement was not found. Clear melanin-containing cell aggregates were found on the top part of the multilayer.
- a matrigel-coated substrate a uniform layer of adherent cells was not found around day 15, and the cells were drawn into the inside of the gel.
- retinal pigment epithelial cells can be produced efficiently by a simple and easy method using a culture substrate coated with laminin-E8 fragment.
- the production method of the present invention is superior in the differentiation induction efficiency and can purify retinal pigment epithelial cells by a simple and easy operation, and can produce retinal pigment epithelial cells in a high yield by suppressing cell loss during the step.
- the retinal pigment epithelial cells produced by the method of the present invention are useful not only for the treatment of retinal diseases but also as normal and disease model cells.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- The present invention relates to a method of efficiently producing retinal pigment epithelial (RPE) cells from human pluripotent stem cells, a method of stably culturing retinal pigment epithelial cells, and the like.
- As a method for producing retinal pigment epithelial cells from pluripotent stem cells, a method called SFEB method including culturing ES cells as a floating aggregate in a serum-free medium (
patent document 1 etc.), a method including inducing differentiation of pluripotent stem cells in the presence of a differentiation-inducing factor on a culture substrate coated with a weakly cell adhesive coating agent and the like (non-patent document 1 etc.) are known. However, due to the low differentiation induction efficiency, these methods require plural steps combining adhesion culture and floating culture to obtain a highly concentrated cell population of retinal pigment epithelial cells, and have problems such as the required presence of a purification step with a high workload and a long time, which includes selectively picking up a colony of pigment cells under an optical microscope. Moreover, these methods have a problem of easy cell loss during passage culture. Therefore, a method capable of stably affording highly pure retinal pigment epithelial cells by a simple and easy method has been demanded. - For maintenance culture of human pluripotent stem cells, a method using an extracellular matrix instead of a feeder cell has been widely used. Among others, laminin is being preferably used and, for example,
non-patent document 2 reports successful maintenance culture of human ES cell on laminin-511 for a long term. As for E8 fragment known as an altered laminin having an improved cell adhesion activity, for example,patent document 2 andnon-patent document 3 disclose culture methods of human pluripotent stem cells, which use E8 fragment of human laminin-α5β1γ1 (laminin-511E8, hereinafter indicated in the same manner) and human laminin-322E8.Non-patent document 4 describes that laminin-511E8 maintains binding activity to α6β1 integrin, which is of the same level as that of full-length laminin-511, andpatent document 2 describes that, by using said laminin-511E8, pluripotent stem cells can be stably immobilized on a culture dish, as a result of which the cells, while maintaining differentiation pluripotency, can be subjected to maintenance culture. However, no report has documented utilization of such E8 fragment of laminin for other than culture of pluripotent stem cells, for example, differentiation induction of pluripotent stem cells and the like. - On the other hand, as a method of inducing differentiation of human pluripotent stem cells into retinal pigment epithelial cells in the absence of a feeder cell, a method using laminin is known. For example,
non-patent document 5 describes that the differentiation induction efficiency into retinal pigment epithelial cells markedly increased by adhesion culture of pluripotent stem cells on laminin-111 and Matrigel. However, no report has documented use of the E8 fragment of laminin for the induction of differentiation of pluripotent stem cell into retinal pigment epithelial cell. -
- patent document 1: WO 2005/123902
- patent document 2: WO 2011/043405
-
- non-patent document 1: PLoS One. 2012; 7 (5): e37342.
- non-patent document 2: Nature Biotech. June 2010; 28(6): 611-5
- non-patent document 3: Nat. Commun. 3:1236 doi: 10.1038/ncomms2231
- non-patent document 4: J Biol Chem. 284:7820-7831, 2009
- non-patent document 5: J. Tissue Eng Regen Med 2013; 7: 642-653
- An object of the present invention is to provide a production method of retinal pigment epithelial cell that improves differentiation induction efficiency of pluripotent stem cell into retinal pigment epithelial cell, and can provide highly pure retinal pigment epithelial cell by a simple and easy operation in a short period, a culture method of retinal pigment epithelial cell that can stably grow and culture a cell, a toxicity/efficacy evaluation method using a retinal pigment epithelial cell useful for transplantation therapy, and a therapeutic drug for a retinal disease.
- The present inventors have conducted intensive studies in an attempt to achieve the above-mentioned objects and found that, when human pluripotent stem cells are cultured on a culture substrate coated with laminin-E8, the seeded pluripotent stem cells rapidly adhere to the culture substrate, a large amount of pigment cell is generated from early stages, the yield of retinal pigment epithelial cells can be markedly improved, cells are not easily lost during medium exchange, the purification step can be simplified, and a highly pure cell population can be obtained in a short period. As a result, the operability and economic efficiency, which are the problems in inducing differentiation of pluripotent stem cells into retinal pigment epithelial cells, can be markedly improved, and the retinal pigment epithelial cells of interest can be produced stably and efficiently, which resulted in the completion of the present invention.
- That is, the present invention relates to the following.
- [1] A production method of retinal pigment epithelial cells, comprising a step of adhesion culture of human pluripotent stem cells on a culture substrate coated with a laminin-E8 fragment.
[2] The method of [1], wherein the laminin-E8 fragment is laminin-511E8 fragment.
[3] The method of [1] or [2], wherein the step of adhesion culture is performed in the presence of a differentiation-inducing factor.
[4] The method of any of [1]-[3], wherein the human pluripotent stem cells are human iPS cells.
[5] A retinal pigment epithelial cell produced by adhesion culture of human pluripotent stem cells on a culture substrate coated with a laminin-E8 fragment.
[6] A retinal pigment epithelial cell sheet produced by adhesion culture of human pluripotent stem cells on a culture substrate coated with a laminin-E8 fragment.
[7] An amplification method of retinal pigment epithelial cells, comprising a step of adhesion culture of retinal pigment epithelial cells on a culture substrate coated with a laminin-E8 fragment.
[8] A purification method of retinal pigment epithelial cells, comprising a step of adhesion culture of retinal pigment epithelial cells on a culture substrate coated with a laminin-E8 fragment.
[9] A therapeutic drug for a retinal disease, comprising retinal pigment epithelial cells produced by the method of any of [1]-[4], or retinal pigment epithelial cells cultured by the method of [7]. - According to the present invention, retinal pigment epithelial cells can be produced in a high yield from pluripotent stem cells. In addition, differentiation induction efficiency is improved, and a cell population containing retinal pigment epithelial cells at a high concentration can be obtained, and highly pure retinal pigment epithelial cells can be produced by a simple and easy purification operation. According to the present invention, moreover, since retinal pigment epithelial cells can be stably adhered, the cells are not easily lost during medium exchange, and can be stably passaged.
-
FIG. 1 is a schematic showing of the structure of laminin-E8. -
FIG. 2 shows expression of RPE-related genes by RPE cells induced from human iPS cells (201B7). -
FIG. 3 shows the cell adhesion state ondays -
FIG. 4 shows cell populations ondays - The present invention is a production method of retinal pigment epithelial cells, comprising a step of adhesion culture of human pluripotent stem cells by using a culture substrate coated with a laminin-E8 fragment (hereinafter to be referred to as “the production method of the present invention”).
- The “pluripotent stem cell” in the present invention means a stem cell having self-replication competence and differentiation pluripotency, and is not particularly limited. For example, embryonic stem cells (ES cell), induced pluripotent stem cells (iPS cell) and the like are widely utilized. Preferably, human ES cells or human iPS cells are utilized and, more preferably, human iPS cells are utilized.
- The “iPS cell” in the present invention means a cell that artificially acquired self-replication competence and differentiation pluripotency by contacting a nuclear reprogramming factor with somatic cells (e.g., fibroblast, skin cell, lymphocyte etc.). The production method of iPS cells in the present invention is not particularly limited.
- The “retinal pigment epithelial cell” in the present invention refers to an epithelial cell constituting the retinal pigment epithelium, and a progenitor cell thereof. Whether a retinal pigment epithelial cell or not can be confirmed by, for example, expression of cell markers (RPE65, CRALBP, MERTK, BEST1 etc.), cell forms (intracellular melanin dye deposition, polygonal and flat cell form, formation of polygonal actin bundle etc.) and the like. The progenitor cell of retinal pigment epithelial cell means a cell directed to be induced to differentiate into retinal cell, and whether a progenitor cell or not can be confirmed by expression of cell markers (Mitf, Pax6, Rx, Crx etc.) and the like. Functional evaluation of retinal pigment epithelial cell can be confirmed using, for example, secretability, phagocytic capacity and the like of cytokine (VEGF, PEDF etc.) as an index. These functional evaluation and confirmation operations can be performed by those of ordinary skill in the art by setting appropriate conditions.
- The “laminin” in the present invention is a heterotrimer molecule consisting of α, β, γ chains, and is an extracellular matrix protein containing isoforms having different subunit chain compositions. Specifically, laminin has about 15 kinds of isoforms including heterotrimers of combinations of 5 kinds of α chain, 4 kinds of ρ chain and 3 kinds of γ chain. The number of each of α chain (α1-α5), β chain (β1-β4) and γ chain (γ1-γ3) is combined to determine the name of laminin. For example, a laminin composed of a combination of al chain, β1 chain, γ1 chain is named laminin-111, a laminin composed of a combination of α5 chain, β1 chain, γ1 chain is named laminin-511, and a laminin composed of a combination of α5 chain, β2 chain, γ1 chain is named laminin-521. As laminin, for example, a laminin derived from a mammal can be used. Examples of the mammal include mouse, rat, guinea pig, hamster, rabbit, cat, dog, sheep, swine, bovine, horse, goat, monkey and human. Human laminin is preferably used when retinal pigment epithelial cells are produced for the purpose of transplanting to human, and the like. At the present stage, human laminin is known to include 15 kinds of isoforms.
- Laminin-E8 fragment was originally one of the fragments obtained by digesting mouse laminin-111 with elastase, and identified as a fragment having strong cell adhesion activity (EMBO J., 3:1463-1468, 1984, J. Cell Biol., 105:589-598, 1987). When digested with elastase, the presence of a fragment corresponding to the E8 fragment of mouse laminin-111 is assumed in laminin other than mouse laminin-111. However, separation and identification of E8 fragment by digestion of laminin other than mouse laminin-111 with elastase has not been reported heretofore. Therefore, laminin-E8 fragment to be used in the present invention is not required to be an elastase digestion product of each laminin, but may be a recombinant as long as it is a fragment of laminin having a cell adhesion activity similar to that of each corresponding laminin and having a structure corresponding to that of E8 fragment digested with elastase. That is, the “laminin-E8 fragment (hereinafter sometimes to be indicated as “laminin-E8”)” in the present invention refers to a molecule constituting a heterotrimer in each C-terminal region of α chain, β chain and γ chain, maintaining a binding activity to integrin, as well as maintaining a cell adhesion activity. Laminin-E8 shows integrin binding specificity that varies for each laminin isoform, and can exert a strong adhesion activity to a cell that expresses the corresponding integrin.
- When concretely explained, laminin-E8 in the present invention is a laminin fragment having,
- (1) functionally, cell adhesion activity at least equivalent to that of full-length laminin, and at least equivalent integrin binding activity, and
(2) structurally, a structure corresponding to that of mouse laminin-E8, specifically, a structure corresponding to a region from coiled-coil C-terminal region of laminin trimer to 1st-3rd of G domain. It is explained in more detail in the following from the (1) functional aspect and (2) structural aspect. - Examples of the laminin-E8 in the present invention include a molecule showing binding specificity to at least one of the integrins expressed on the surface of human pluripotent stem cell and/or human retinal pigment epithelial cell, preferably, a molecule showing binding specificity to an integrin expressed on the surface of both human pluripotent stem cells and human retinal pigment epithelial cells, and an integrin expressed on the surface of human retinal pigment epithelial cells are preferably used. Examples of the integrin expressed on the surface of human pluripotent stem cell include α6β1 integrin and the like, and examples of the integrin expressed on the surface of human retinal pigment epithelial cell include α6β1 integrin, α3β1 integrin, α7β1 integrin and the like.
- Laminin-E8 in the present invention shows binding specificity to integrin at least equivalent to each laminin. Laminin-E8 showing particularly strong affinity to integrin is preferably used. “Laminin-E8 showing particularly strong affinity to integrin” is one showing a significantly low dissociation constant as measured by a known method and, for example, the dissociation constant measured by, for example, the method shown in Table 1 of The Journal of Biological Chemistry (2009) 284, pp. 7820-7831 is not more than 10 nM.
- As laminin-E8 in the present invention, one having a strong cell adhesion activity is preferably used. The “laminin-E8 having a strong cell adhesion activity” is one showing a significantly strong adhesion activity in a cell adhesion test with measurement by a known method and shows an adherent cell number of not less than 400 cells/mm2 at a coating concentration of laminin-E8 of not more than 10 nM when, for example, the cell adhesion assay described in The Journal of Biological Chemistry (2007) 282, pp. 11144-11154 is performed.
- In the present invention, as laminin-E8, one showing binding specificity to α6β1 integrin, capable of stably adhering pluripotent stem cells in the initial stage of differentiation induction, and capable of stably adhering retinal pigment epithelial cells in the latter stage of differentiation induction or progenitor cells thereof is preferably used. From such aspect, particularly, laminin-511 E8 is highly preferable among laminin-E8, since it has binding specificity to α3β1 integrin and α7β1 integrin in addition to α6β1 integrin, and can contribute to the improvement of differentiation induction efficiency of pluripotent stem cells into retinal pigment epithelial cells, or stabilization of maintenance culture of retinal pigment epithelial cells, by improving the adhesion activity to retinal pigment epithelial cells.
- The laminin-E8 in the present invention is, as mentioned above or shown in
FIG. 1 , a laminin fragment structurally corresponding to a fragment having a cell adhesion activity (E8 fragment) in an elastase digestion product of mouse laminin-111. That is, it maintains a part of domain II (triple-stranded coiled-coil domain) of full-length laminin (E8 fragment depicted inFIG. 1 does not show such manner but actually maintains a coiled-coil structure), and forms a short coiled-coil structure on the N terminal side of E8 with a corresponding fragment of β chain and a corresponding fragment of γ chain. On the C-terminal side of E8, the G1-G3 domain structure of α chain is maintained. The β chain and γ chain are bonded to each other by forming a disulfide bond via a cysteine residue on each C-terminal side. - As described above, laminin-E8 in the present invention may be an enzyme-treated product obtained by treating natural laminin with elastase, or a recombinant produced by gene recombination. When the laminin-E8 in the present invention is a recombinant, a tag may be bonded to the N terminal for the purpose of purification and the like as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and the cell adhesiveness is not impaired. Such tag is not particularly limited and, for example, His tag, Flag tag, HA tag and the like can be mentioned. Also, the sequence of the linker region between the tag and laminin-E8 is not particularly limited as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and cell adhesiveness is not impaired.
- In the laminin-E8 in the present invention, a part of the amino acid sequence may be deleted, added, or substituted as long as the binding activity of the corresponding laminin to integrin is maintained, and the cell adhesiveness thereof is not impaired.
- While E8 fragment generally lacks two G domains (G4 and G5) on the α chain C-terminal side, the G4, G5 domains may be partly or entirely contained in the laminin-E8 in the present invention as long as the binding activity of the corresponding full-length (natural) laminin to integrin is maintained, and cell adhesiveness thereof is not impaired. For example, the G4, G5 domains may be partly or entirely contained in the laminin-511 E8 as long as the binding activity to integrin α6β1 of the equivalent level as laminin-511 is maintained, and the cell adhesion activity is not impaired.
- Like full-length laminin, β chain and γ chain of laminin-E8 are bonded via cysteine on the C-terminal side of the coiled-coil part. Since the cysteine influences the integrin binding activity, it is desirably not substituted or deleted. Furthermore, since the C-terminal side amino acid following said cysteine in the γ chain also influences the integrin binding activity, it is desirably at least not deleted (J Biol Chem. 2007 Apr. 13; 282(15):11144-54).
- Specific examples of such laminin-E8 include rhLM511E8 produced in Example (3) of WO 2011/043405. Said laminin-511E8 can be preferably utilized as the laminin-E8 in the present invention.
- The “culture substrate” to be used in the present invention can be produced by coating a surface of an incubator with the laminin-E8 in the present invention. As used herein, “coating” a surface of an incubator means adsorption of laminin-E8 to the surface of the incubator by some interaction between laminin-E8 and the incubator surface, where the orientation of the laminin-E8 does not pose a particular problem in affording the effect of the present invention. The incubator is not particularly limited as long as it can be used for cell culture and, for example, dish (also referred to as culture dish), petri dish and plate (microtiter plate, microplate, deep well plate etc. of 6 well, 24 well, 48 well, 96 well, 384 well, 9600 well and the like), flask, chamber slide, tube, Cell Factory, roller bottle, spinner flask, hollow fiber, microcarrier, bead and the like can be mentioned. The culture substrate in the present invention may be applied with an appropriate surface treatment as long as the cell adhesion property by laminin-E8 is not impaired.
- The “adhesion culture” in the present invention means culture in a state where the cells of interest are adhered to the bottom of the incubator via laminin-E8, and do not float in the culture medium even when the incubator is gently shaken during culture. Since laminin-E8 to be used in the present invention shows extremely superior cell adhesiveness, the cells after cell seeding are preferably uniformly dispersed by a method including rapidly trembling the incubator and the like. The cells of interest may be subjected to floating culture in an incubator containing laminin-E8 before and after the adhesion culture, as long as the object of the present invention can be achieved.
- The medium is constituted of a basal medium, a serum and/or a serum replacement, and other components. As the basal medium, one or plural kinds of synthetic media generally used for culturing mammalian cells can be used in combination and, for example, commercially available products such as DMEM, GMEM and the like can be obtained.
- As the serum, a serum derived from a mammal such as bovine, human and the like can be used. The serum replacement is a low-protein replacement that replaces serum such as FBS and the like used for the cell culture, and commercially available products such as Knockout Serum Replacement (KSR), Chemically-defined Lipid concentrated (manufactured by Gibco), Glutamax (manufactured by Gibco) and the like, as well as N2, B27 and the like which are serum replacements for nerve cell culture can be obtained. In the present invention, a serum replacement is preferable, and KSR is particularly preferable from the aspect of quality management of the cell of interest.
- The concentration of serum or serum replacement can be appropriately set within the range of, for example, 0.5-30% (v/v). The concentration may be constant, or gradually changed. For example, the concentration may be lowered in stages at intervals of about 1-3 days (preferably 2 days). For example, serum or serum replacement can be added at 3 stages of concentration of 20%, 15% and 10%.
- As other component constituting the medium, a Rho kinase inhibitor such as Y-27632 and the like can be used to suppress cell death of human pluripotent stem cells dispersed in a culture medium. A Rho kinase inhibitor may be added in the period of a part or the whole period of the differentiation induction step. For example, unnecessary cells that did not differentiate into the cell of interest can be removed by cell death by using a medium free of a Rho kinase inhibitor in the latter period of the differentiation induction step.
- The medium can contain other components generally used for culturing mammalian cells, besides those mentioned above.
- The concentration of human pluripotent stem cells to be used in the production method of the present invention is not particularly limited as long as pluripotent stem cells can be uniformly seeded, and adhesion culture is possible. For example, when a 10 cm dish is used, it is 1×105-1×108 cells, preferably 2×106-5×107 cells, more preferably 5×105-9×106 cells, per 1 dish.
- The adhesion culture in the production method of the present invention can also be performed in the presence of a differentiation-inducing factor. As the differentiation-inducing factor, a factor known as a factor promoting differentiation induction into the cell of interest can be utilized. Since the production method of the present invention includes differentiation induction into retinal pigment epithelial cells, a differentiation-inducing factor into retinal pigment epithelial cells is desirably used. Examples of the differentiation-inducing factor into retinal pigment epithelial cells include Nodal signal inhibitor, Wnt signal inhibitor, Sonic hedgehog signal inhibitor, and Activin signal promoter and the like.
- The Nodal signal inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Nodal, and protein, nucleic acid, low-molecular-weight compound and the like can be used. Examples of the Nodal signal inhibitor include protein, peptide or nucleic acid such as Lefty-A, soluble Nodal receptor, anti-Nodal antibody, Nodal receptor inhibitor and the like; low-molecular-weight compound such as SB-431542 and the like, and the like. Particularly, a low-molecular-weight compound such as SB-431542 and the like which is easily available and shows less difference between lots is preferable.
- The Wnt signal inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Wnt, and protein, nucleic acid, low-molecular-weight compound and the like can be used. Examples of the Wnt signal inhibitor include protein, peptide or nucleic acid such as Dkkl, Cerberus protein, Wnt receptor inhibitor, soluble Wnt receptor, Wnt antibody, casein kinase inhibitor, dominant negative Wnt protein and the like; and low-molecular-weight compound such as CKI-7 (N-(2-aminoethyl)-5-chloro-isoquinoline-8-sulfonamide), D4476 (4-{4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl}benzamide), IWR-1-endo(IWR1e), IWP-2 and the like. Particularly, a low-molecular-weight compound which is easily available and shows less difference between lots is preferable. Among others, a low-molecular-weight compound having an activity to selectively inhibit casein kinase I is preferable and, for example, CKI-7, D4476 and the like can be utilized.
- Examples of the Activin signal promoter include protein belonging to the Activin family, Activin receptor, Activin receptor agonist and the like.
- The concentration of these differentiation-inducing factors can be appropriately selected according to the kind of the differentiation-inducing factor. Specifically, when SB-431542 is used as a Nodal signal inhibitor, the concentration is, for example, 0.01-50 μM, preferably 0.1-10 μM, more preferably 5 μM; when CKI-7 is used as a Wnt signal inhibitor, it is added at the concentration of 0.01-30 μM, preferably 0.1-30 μM, more preferably 3 μM.
- In the production method of the present invention, a combination of a Nodal signal inhibitor (e.g., SB-431542) and a Wnt signal inhibitor (e.g., CKI-7) is preferably used as a differentiation-inducing factor.
- Culture according to the aforementioned method induces differentiation of pluripotent stem cells into retinal pigment epithelial cells, whereby retinal pigment epithelial cells can be generated generally on day 25-45 from the seeding of pluripotent stem cells. Generation of retinal pigment epithelial cell can be confirmed according to the aforementioned method. When generation of retinal pigment epithelial cells is confirmed, the medium is exchanged with a maintenance medium for retinal pigment epithelial cells and, for example, the cells are preferably further cultured for 5-10 days while exchanging the total amount of medium at a frequency of not less than once in 3 days. As a result, a melanin dye deposition cell population and a polygonal flat cell population adhered to the basal lamina can be observed more clearly.
- As the maintenance medium for retinal pigment epithelial cells, for example, those described in IOVS, March 2004, Vol. 45, No. 3, Masatoshi Haruta, et. al., IOVS, November 2011, Vol. 52, No. 12, Okamoto and Takahashi, J. Cell Science 122 (17), Fumitaka Osakada, et. al., IOVS, February 2008, Vol. 49, No. 2, Gamm, et. al. can be used, which are constituted of a basal medium, a serum and/or a serum replacement, and other components. As the basal medium, one or plural kinds of synthetic media generally used for culturing mammalian cells can be used in combination and, for example, commercially available products such as DMEM, GMEM and the like can be obtained.
- As the serum, a serum derived from a mammal such as bovine, human, swine and the like can be used. The serum replacement is a low-protein replacement that replaces serum such as FBS and the like used for the cell culture, and commercially available products such as Knockout Serum Replacement (KSR), Chemically-defined Lipid concentrated (manufactured by Gibco), Glutamax (manufactured by Gibco) and the like, as well as N2, B27 and the like which are serum replacements for nerve cell culture can be obtained. In the present invention, a serum replacement is preferable, and B27 is particularly preferable from the aspect of quality management of the cell of interest.
- Examples of other components include L-glutamine, penicillin sodium, sulfuric acid streptomycin and the like.
- The production method of the present invention may further contain a step of purifying retinal pigment epithelial cells by a concentration operation. Since the production method of the present invention markedly improves the differentiation induction efficiency, a highly pure retinal pigment epithelial cell can be obtained in a short production period by a simple and easy operation. A method of concentrating retinal pigment epithelial cells is not particularly limited as long as it is generally known as a method of concentrating cells and, for example, methods such as filtration, centrifugation, perfusion separation, flow cytometry separation, trap separation by antibody immobilized carrier and the like can be used. Preferably, a method such as filtration using nylon mesh and the like can be utilized.
- According to the production method of the present invention, human pluripotent stem cells can be rapidly adhered to an incubator via laminin-E8 superior in cell adhesion, and culture in an immobilized state markedly improves differentiation induction efficiency and, moreover, cell loss during medium exchange can be suppressed. Therefore, cell population of retinal pigment epithelial cells at a high concentration can be obtained in a large amount. Furthermore, cell purification can be performed by a simple and easy operation, the time necessary for a purification step can be shortened, and retinal pigment epithelial cells can be produced extremely efficiently. In addition, according to the production method of the present invention, retinal pigment epithelial cells can be adhered to each other to form a sheet-like structure. Therefore, a sheet of retinal pigment epithelial cells can be produced by the production method of the present invention. The sheet of retinal pigment epithelial cells is useful as a cell population to be used as a cell transplantation therapeutic drug for the treatment of retinal diseases, as described in detail below in 3.
- The present invention also relates to an amplification method of retinal pigment epithelial cells, comprising a step of adhesion culture of retinal pigment epithelial cells by using a culture substrate coated with laminin-E8 (hereinafter to be referred to as “the amplification method of the present invention”). According to the amplification method of the present invention, retinal pigment epithelial cells can be easily grown by a convenient method.
- As the retinal pigment epithelial cell in the amplification method of the present invention, retinal pigment epithelial cells derived from a mammal can be used. Examples of the mammal include mouse, rat, guinea pig, hamster, rabbit, cat, dog, sheep, swine, bovine, horse, goat, monkey and human. Human retinal pigment epithelial cell is preferably used when retinal pigment epithelial cells are produced for the purpose of transplanting to human, and the like.
- The retinal pigment epithelial cell in the amplification method of the present invention refers to epithelial cells constituting retinal pigment epithelium, and progenitor cells thereof. Examples thereof include retinal pigment epithelial cell derived from a living organism; retinal pigment epithelial cell induced to differentiate from an undifferentiated cell (pluripotent stem cell, precursor of retinal pigment epithelial cell etc.); retinal pigment epithelial cell transdifferentiated from a differentiated cell or a precursor of a cell other than retinal pigment epithelial cell etc., preferably a retinal pigment epithelial cell induced to differentiate from an undifferentiated cell, more preferably a retinal pigment epithelial cell induced to differentiate from a pluripotent stem cell, which is obtained by the above-mentioned production method of the present invention.
- The concentration of the retinal pigment epithelial cells used for the amplification method of the present invention is not particularly limited as long as uniform adhesion culture of retinal pigment epithelial cells is possible. For example, when a 10 cm dish is used, it is 1×105-1×108 cells, preferably 2×106-5×107 cells, more preferably 5×105-1×107 cells, per 1 dish.
- The laminin-E8 fragment in the amplification method of the present invention is similar to that mentioned above, and a coating method of a culture substrate is also similar. Therefore, by culturing the retinal pigment epithelial cells obtained by the above-mentioned production method of the present invention on the same incubator coated with the laminin-E8 fragment, the obtained retinal pigment epithelial cells can be directly amplified in situ and can be obtained in large amounts. According to the amplification method of the present invention, moreover, the cells contained in the differentiation-induced retinal pigment epithelial cells, which could not be induced to differentiate can be relatively reduced. Therefore, the amplification method of the present invention can also be used as a purification method of retinal pigment epithelial cells.
- As the laminin-E8 to be used in the amplification method of the present invention, particularly, laminin-511 E8 is preferable among laminin-E8, since it has binding specificity to α3β1 integrin and α7β1 integrin in addition to α6β1 integrin, and can contribute to the stabilization of maintenance culture of retinal pigment epithelial cells and cell proliferation, by improving the adhesion activity to retinal pigment epithelial cells.
- According to the amplification method of the present invention, since retinal pigment epithelial cells are rapidly fixed on an incubator via laminin-E8 superior in cell adhesiveness, cell loss during medium exchange can be suppressed, and deformation of cell form due to passage can be suppressed, the maintenance culture and culture growth of retinal pigment epithelial cells can be performed stably. According to the amplification method of the present invention, moreover, a membranous retinal pigment epithelial cell group can also be utilized directly or after recovery by separation from the culture substrate, as a therapeutic drug for retinal diseases shown below.
- The retinal pigment epithelial cells obtained by the production method or amplification method of the present invention are cultured on laminin-E8, particularly laminin-511 E8. Therefore, they can be easily recovered by separation from the culture substrate singly as cells, or as a sheet, and have superior property.
- The retinal pigment epithelial cells produced by the production method of the present invention, and the retinal pigment epithelial cells amplification by the amplification method of the present invention can be used as a cell transplantation therapeutic drug to be transplanted in the form of a suspension or sheet to living organisms for the treatment of retinal diseases. Retinal disease is an ophthalmic disease relating to the retina and also includes complications with other diseases such as diabetes and the like.
- The retinal pigment epithelial cells produced by the production method of the present invention can be utilized as a normal or disease model cell for screening for therapeutic drugs for retinal diseases and therapeutic drug for diseases of other complications such as efficacy evaluation diabetes and the like, or prophylactic drug thereof, safety test of chemical substances and the like, stress test, toxicity test, side effect test, infection/contamination test. On the other hand, they can also be utilized for toxicity study, toxicity test and the like of phototoxicity unique to retinal cells, retinal excitotoxicity and the like. The evaluation method thereof includes stimulation, toxicity tests such as apoptosis evaluation and the like, as well as tests for evaluation of influence on normal differentiation from progenitor cell into retinal pigment epithelial cell and visual cell (expressed protein analysis and phagocytic capacity test by RT-PCR of various gene markers, ELISA of cytokine and the like), toxicity test of phototoxicity and the like, retinal electric potential and transepithelial impedance on visual function, cell injury test caused by autoimmune reaction and the like. As a cell material for these tests, not only retinal pigment epithelial cells but also progenitor cells thereof can be used and, for example, a plate on which cells are adhered by seeding, a cell suspension, a sheet or compact thereof can be provided. They can be used as an extrapolation test of human and animal tests.
- The contents disclosed in any publication cited in the present specification, including patents and patent applications, are hereby incorporated in their entireties by reference, to the extent that they have been disclosed herein.
- The present invention is explained in more detail in the following by referring to Examples, which are not to be construed as limitative.
-
-
- differentiation induction basic medium (GMEM medium (Invitrogen), KSR (Invitrogen), 0.1 mM MEM non-essential amino acid solution (Invitrogen), 1 mM pyruvic acid sodium (SIGMA), 0.1 M 2-mercaptoethanol (Wako Pure Chemical Industries, Ltd.), 100 U/ml penicillin-100 μg/ml streptomycin (Invitrogen))
- primary differentiation induction medium (differentiation induction basic medium containing 20% KSR, 10 μM Y-27632 (Wako Pure Chemical Industries, Ltd.), 5 μM SB431542 (SIGMA), 3 μM CKI-7 (SIGMA))
- secondary differentiation induction medium (differentiation induction basic medium containing 15% KSR, 10 μM Y-27632 (Wako Pure Chemical Industries, Ltd.), 5 μM SB431542 (SIGMA), 3 μM CKI-7 (SIGMA))
- tertiary differentiation induction medium (differentiation induction basic medium containing 10% KSR, 10 μM Y-27632 (Wako Pure Chemical Industries, Ltd.), 5 μM SB431542 (SIGMA), 3 μM CKI-7 (SIGMA))
- quaternary differentiation induction medium (differentiation induction basic medium containing 10% KSR)
- RPE maintenance medium (67% DMEM low glucose (SIGMA), 29% F12 (SIGMA), 1.9 mM L-glutamine (Invitrogen), 1.9% B-27 supplement (Invitrogen), 96 U/mL penicillin sodium, 96 μg/mL streptomycin sulfate)
- iPS cells (112007, provided by Kyoto University) derived from human peripheral blood (mononuclear cell) were seeded in a laminin-coated culture dish (manufactured by Sumitomo Bakelite Co., Ltd.) at 9×106 cells/9 cm dish. The laminin-coated culture dish was produced by coating a 9 cm culture dish (BD FALCON) with a 0.5 μg/cm2 aqueous solution of laminin-511 E8 fragment (protein disclosed in Example (3) of WO 2011043405. (manufactured by Nippi (iMatrix-511, NIP-8920-02))) at 37° C. for not less than 1 hr. iPS cells rapidly adhered on the culture dish, and formation of floating aggregate was not confirmed.
- The above-mentioned differentiation induction was performed according to the following timeline, and differentiation induction in the Examples and Comparative Examples in the present specification followed this timeline. With the first day of culture as Day 0, the total amount of the medium was exchanged every day from the start of the culture (Day 1) to around
Day 40 when pigment cell was confirmed. The composition of the medium was changed in stages as shown below. That is, the primary differentiation induction medium (20% KSR) was used for Day 1-4, the secondary differentiation induction medium (15% KSR) was used for Day 5-8, the tertiary differentiation induction medium (10% KSR) was used for Day 9-12, and the quaternary differentiation induction medium (10% KSR) was used from Day 13 to aroundDay 40 when pigment cells are confirmed. - After around
Day 40 when pigment cells were confirmed, the total amount of the medium was exchanged with RPE maintenance medium up to Day 47 at not less than once per 3 days. As the culture proceeded, the cell pigment became darker, and on Day 47, many cell groups containing dark pigments were observed. On Day 47, a cell population containing pigment cells was recovered. - Using laminin-511 E8 fragment as a coating agent, seeded iPS cells rapidly adhered to the culture dish at a high density, and stably maintained an adhesion state even during culture period in a differentiation induction medium. Therefore, the cell loss could be suppressed low even when the total amount of medium was repeatedly exchanged. Furthermore, the rate of generation of pigment cells was drastically improved and the differentiation induction efficiency was markedly improved as compared to when the iPS cells were seeded on an incubator coated with collagen.
- By a method similar to that of Example 1 except that iPS cells (201B7, provide by Kyoto University) derived from human skin (fibroblast) were used instead of iPS cells (112007, provide by Kyoto University) derived from human peripheral blood (mononuclear cell) were used, pigment cells were obtained.
- As a result, like Example 1, the rate of generation of pigment cells relative to the seeded iPS cells was drastically improved and the differentiation induction efficiency was markedly improved.
- The cell population containing pigment cells on Day 47, which underwent adhesion culture in the culture dish in Example 1 and Example 2, was treated with 0.01% Trypsin-0.53 mM EDTA and cell aggregates were detached from the culture dish. Then, adhesion between the cells was detached by mild pipetting. Protease liquid and residual impurities thereof in the cell mixture were removed together with the supernatant by centrifugation, then, unnecessary cells were separated by filtration separation through a cell strainer (DB
Falcon Cell Strainer 40 μm Nylon), and a cell population containing RPE cells was recovered (Day 48). - The obtained cells were seeded in RPE maintenance medium described in Example 1 in the same 5 culture dishes coated with laminin-511 E8 as in Example 1 at 9×106 cells/9 cm dish, and standing culture was performed until around Day 50 when adhesion of the RPE cell colony was confirmed.
- From Day 51 to Day 71, the total amount of the medium was exchanged with RPE maintenance medium not less than once in 3 days for 3 weeks, then subjected to filtration separation using a filter, seeded in each of the same 5 culture dishes coated with laminin-511 E8, and similarly cultured for 2 weeks. As a result, retinal pigment epithelial cells were amplified to the yield of 25 dishes (10 cm dish) from any cell populations of Example 1 and Example 2. The purity (n=4) of the obtained cell populations was 96.4%, 100%, 98.6% or 99.6%.
- As one example, the purity calculation data of a dish with 98.6% purity is shown.
-
TABLE 1 purity calculation data of RPE cell with 98.6% purity positive cell pigment negativity negative cell Bestrophin, Bestrophin, total visual pigment Bestrophin Pax6 Pax6 Pax6 positive total purity field positive positive positive both positive both negative cells cells (%) 1 11 0 0 6 0 17 17 98.6 2 176 5 33 30 4 244 248 3 88 0 0 14 1 102 103 - As for purity, immunostaining for Pax6 and Bestrphin was performed, and when either was stained, the cell was judged to be an RPE cell. When fluorescence was not observed, the presence or absence of intracellular melanin pigment was examined, and the cell was judged to be an RPE cell based on the confirmation of the pigment (since some pigments inhibit fluorescence observation, cell was judged to be RPE cell in the presence of pigment even when fluorescence was not observed). The purity was determined by a method including adding each as positive cells.
- This Example afforded similar results even when iPS cells of a different line (201B7) were used.
- By a method similar to that of Example 1 except that, in the differentiation induction step of Example 1, floating culture was performed using a non-adhesive culture dish (Nunc) treated with MPC (2-methacryloxylethyl phosphoryl choline) instead of adhesion culture using a culture dish coated with laminin-511 E8 (BD FALCON), a differentiation induction step was performed.
- As a result, almost all pigment cells were lost during medium exchange in the differentiation induction step, pigment cell could not be recovered on Day 47.
- By a method similar to that in Example 1 except that, in the differentiation induction step of Example 1, adhesion culture was performed using a culture dish coated with poly-D lysine and gelatin instead of a culture dish coated with laminin-511 E8, differentiation induction was performed.
- The adhesiveness of the cell to the poly-D lysine/gelatin-coated culture dish was weak as compared to the laminin-511 E8-coated culture dish, and the cells were easily lost during medium exchange. Therefore, the rate of the pigment cells on Day 47 after the start of the culture was not more than 1/20 of Example 1 by visual observation of the number of pigment cells relative to the total cells in the culture dish, and differentiation induction efficiency was also markedly low.
- The pigment cells obtained in Examples 1-3 were subjected to RT-PCR analysis using primers having the following sequences, according to the method described in Journal of Cell Science 2009 Sep. 1 122 3169-79. As a result, expression of RPE cell specific genes (RPE65, CRALBP, MERTK, BEST1) was found, similar to commercially available human RPE cell lines, thus confirming RPE cells.
-
RPE65-F (SEQ ID NO: 1) TCC CCA ATA CAA CTG CCA CT RPE65-R (SEQ ID NO: 2) CCT TGG CAT TCA GAA TCA GG CRALBP-F (SEQ ID NO: 3) GAG GGT GCA AGA GAA GGA CA CRALBP-R (SEQ ID NO: 4) TGC AGA AGC CAT TGA TTT GA MERTK-F (SEQ ID NO: 5) TCC TTG GCC ATC AGA AAA AG MERTK-R (SEQ ID NO: 6) CAT TTG GGT GGC TGA AGT CT BEST1-F (SEQ ID NO: 7) TAG AAC CAT CAG CGC CGT C BEST1-R (SEQ ID NO: 8) TGA GTG TAG TGT GTA TGT TGG - This Example afforded similar results even when iPS cells of a different line (201B7) were used. As a representative Example, the results obtained using RPE65 are shown in
FIG. 2 . - The pigment cells obtained in Examples 1-3 were detected for the production amount of PEDF by ELISA according to the method described in IOVS. 2006 47 612-3624. As a result, it was confirmed that they similarly had cytokine secretional capacity like the RPE cells of adult retina (Table 2).
-
TABLE 2 PEDF secretion amount days concentration (ng/mL) after standard passage Example 1 Example 2 Example 3 mean error 7 945.2 998.8 993.3 979.1 17.0 10 1266.1 1263.1 1288.0 1272.4 7.9 12 1574.3 1567.0 1616.3 1585.8 15.4 14 1542.0 1622.4 1524.3 1562.9 30.2 17 1621.2 1533.5 1482.9 1545.8 40.4 19 1727.7 1752.7 1842.8 1774.4 35.0 21 1504.8 1581.0 1570.6 1552.1 23.8 - This Example afforded similar results even when iPS cells of a different line (201B7) were used.
- The pigment cells obtained in Examples 1-3 were analyzed for the phagocytic capacity according to the method described in J Cell Sci. 1993 104 37-49, and using FluoSpheres (registered trade mark) fluorescence microsphere (Invitrogen, F13081). As a result, it was confirmed that the cells had phagocytic capacity of the same level as commercially available human RPE cell line. This Example afforded similar results even when iPS cells of a different line (201B7) were used. In addition, similar results were obtained even when the phagocytic capacity was analyzed using iPS cells of a different line (201B7) and pHrod Green E. coli BioParticles (registered trade mark) Conjugate for Phagocytosisb (Molecular Probes, P35366), according to the method described in The Lancet 2012 379 713-720.
- By a method similar to that in Example 1 and using iPS cells (201B7, provided by Kyoto University) derived from human skin (fibroblast) in the same manner as in Example 2 and a culture dish coated with any of the following 1)-3), differentiation induction was performed. A test including simultaneously subjecting 3 substrates to differentiation induction was performed twice, and a supplemental test was performed once for each substrate.
- 1) Laminin-511 E8 (molecular weight 150,000) (iMatrix511: manufactured by Nippi, NIP-8920-02) was used for coating at 0.5 μg/cm2.
2) Human recombinant laminin-511 full-length (molecular weigh t 776,000) (sold by: VERITAS Corporation (produced by: BioLamina)/BLA-LN511) was used for coating at 2.59 μg/cm2.
3) Matrigel (manufactured by BD, 354230 (total protein concentration: 9-12 mg/ml)) (basal lamina matrix, soluble basal lamina preparation derived from mouse Engelbreth-Holm-Swarm (EHS) sarcoma, containing major molecules of basal lamina, type IV collagen, nidogen, perlecan, laminin-111) is dissolved overnight at 4° C., and used in the cold state for coating a culture container at 10 mL/57 cm2 (0.175 ml/cm2). - The state of cell adhesion on
day 1,day 2 andday 3 from the start of differentiation induction is shown inFIG. 3 . In the case of a laminin-511 E8-coated substrate, from the next day of seeding, the cells grew while uniformly adhering to the whole surface of the dish, and rapidly entered the differentiation induction process. In the case of a matrigel (laminin-111)-coated substrate, cell adhesion was inconsistent, with a part invading into the gel, and eventually failed to form a whole surface layer. In the case of a laminin full-length-coated substrate, adhesion was weak and the cells partly formed a colony on the next day of seeding. It took 4-5 days for the cells to grow and spread over the entire surface of the dish. Therefore, the differentiation induction process became uneven to leave a part where differentiation induction did not proceed. - The state of cell population on
day 15 from the start of differentiation induction and before the filtration separation step of the cells (around day 40) is shown inFIG. 4 . In the case of a laminin-511 E8-coated substrate, cells were spread on the entire surface aroundday 15, layered cells were accumulated thick, and melanin color development was observed. Aroundday 40, cells were layered uniformly and thick, and breakage or delamination of the basement was not found. Clear melanin-containing cell aggregates were found on the top part of the multilayer. In the case of a matrigel-coated substrate, a uniform layer of adherent cells was not found aroundday 15, and the cells were drawn into the inside of the gel. Aroundday 40, a clear cellular membrane in a single layer was not formed on the basement side, and melanin color development was not observed. In the case of a laminin full-length-coated substrate, aroundday 15, adherent cells were observed on the whole surface, but differentiation induction did not proceed in many parts, and breakage or delamination of the adhesion surface layer was sometimes found in other lots. In addition, poorly-layered cells were found on the upper part, and melanin color development was extremely weak. The layered cells gradually fell off from around day 20, and the cellular membrane on the basement side was remarkably broken aroundday 40. - From the above, growth failure and differentiation induction failure were observed in the case of a matrigel-coated substrate, and a decrease in the adherent cell number and vulnerability in the number of layered cells were remarkably shown, efficiency of RPE cell appearance shown by melanin color development, and differentiation induction rate thereof were markedly low, and the yield of finally-obtained RPE cells was low in the case of a laminin full-length-coated substrate. Therefore, it was clarified that a culture substrate coated with laminin-E8 fragment in the present invention can produce retinal pigment epithelial cells extremely efficiently.
- According to the production method of the present invention, retinal pigment epithelial cells can be produced efficiently by a simple and easy method using a culture substrate coated with laminin-E8 fragment. The production method of the present invention is superior in the differentiation induction efficiency and can purify retinal pigment epithelial cells by a simple and easy operation, and can produce retinal pigment epithelial cells in a high yield by suppressing cell loss during the step. The retinal pigment epithelial cells produced by the method of the present invention are useful not only for the treatment of retinal diseases but also as normal and disease model cells.
- This application is based on a patent application No. 2013-212345 filed in Japan (filing date: Oct. 9, 2013), the contents of which are incorporated in full herein.
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013212345 | 2013-10-09 | ||
JP2013-212345 | 2013-10-09 | ||
PCT/JP2014/077111 WO2015053375A1 (en) | 2013-10-09 | 2014-10-09 | Method of producing retinal pigment epithelial cell |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160237403A1 true US20160237403A1 (en) | 2016-08-18 |
Family
ID=52813190
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/028,158 Active US11492593B2 (en) | 2013-10-09 | 2014-10-09 | Method for purification of retinal pigment epithelial cells |
US15/028,076 Pending US20160237403A1 (en) | 2013-10-09 | 2014-10-09 | Method of producing retinal pigment epithelial cell |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/028,158 Active US11492593B2 (en) | 2013-10-09 | 2014-10-09 | Method for purification of retinal pigment epithelial cells |
Country Status (11)
Country | Link |
---|---|
US (2) | US11492593B2 (en) |
EP (2) | EP3056563B1 (en) |
JP (4) | JP6518879B2 (en) |
KR (2) | KR102245015B1 (en) |
CN (2) | CN105829526A (en) |
AU (2) | AU2014332857B2 (en) |
BR (1) | BR112016007833B1 (en) |
CA (2) | CA2926721C (en) |
SG (4) | SG11201602734SA (en) |
WO (2) | WO2015053375A1 (en) |
ZA (2) | ZA201603051B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10485829B2 (en) | 2009-11-17 | 2019-11-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
US11371016B2 (en) | 2016-04-22 | 2022-06-28 | Sumitomo Pharma Co., Ltd. | Method for producing retinal tissue |
CN114981417A (en) * | 2019-10-30 | 2022-08-30 | 安斯泰来再生医药协会 | Method for producing retinal pigment epithelial cells |
US11492593B2 (en) | 2013-10-09 | 2022-11-08 | Healios K.K. | Method for purification of retinal pigment epithelial cells |
US11618883B2 (en) | 2017-03-08 | 2023-04-04 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
US11649432B2 (en) | 2015-09-08 | 2023-05-16 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016006915A (en) | 2013-11-27 | 2017-01-23 | Kyoto Prefectural Public Univ Corp | Application of laminin to corneal endothelial cell culture. |
AU2015336454B2 (en) | 2014-10-24 | 2021-04-29 | Riken | Production method for retinal tissue |
CN107073067A (en) | 2014-10-31 | 2017-08-18 | 京都府公立大学法人 | Use the treatment of the new cornea of laminin |
JP6770435B2 (en) * | 2014-10-31 | 2020-10-14 | 京都府公立大学法人 | New treatment of retinal and nerve with laminin |
CN105013010B (en) * | 2015-07-07 | 2018-01-12 | 中山大学中山眼科中心 | A kind of laminin film of auxiliary iPS RPE transplanting |
CA3070215A1 (en) * | 2017-07-20 | 2019-01-24 | Riken | Method for maturation of retinal tissue containing continuous epithelium |
US11684698B2 (en) | 2017-09-08 | 2023-06-27 | Riken | Cell aggregate including retinal tissue and production method therefor |
CN108642014B (en) * | 2018-05-17 | 2019-10-08 | 山东兴瑞生物科技有限公司 | The method for preparing retinal pigment epithelium thin slice using autoimmune cell |
SG11202011929VA (en) * | 2018-06-20 | 2021-01-28 | Biolamina Ab | Methods and compositions for producing retinal pigment epithelium cells |
EP3950953A4 (en) | 2019-03-29 | 2023-04-19 | Public University Corporation Yokohama City University | Screening method and toxicity evaluation method |
JPWO2020218480A1 (en) | 2019-04-26 | 2020-10-29 | ||
WO2021241658A1 (en) | 2020-05-26 | 2021-12-02 | 株式会社ヘリオス | Hypoimmunogenic cells |
EP4201428A1 (en) | 2020-09-11 | 2023-06-28 | Sumitomo Pharma Co., Ltd. | Medium for tissue for transplantation |
TW202302839A (en) | 2021-03-09 | 2023-01-16 | 國立研究開發法人理化學研究所 | Method for producing hypoimmunogenic retinal pigment epithelial cells |
EP4331673A1 (en) | 2021-04-30 | 2024-03-06 | Riken | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
CN115261301B (en) * | 2021-04-30 | 2024-08-06 | 深圳华大生命科学研究院 | In-vitro induction and culture method for retinal pigment epithelial cells |
AU2022390766A1 (en) | 2021-11-19 | 2024-06-20 | Riken | Production method for sheet-like retinal tissue |
CN118541117A (en) | 2022-01-12 | 2024-08-23 | 国立研究开发法人理化学研究所 | Resin-made transplanting head for tissue transplantation, device for tissue transplantation, retinal tissue transplantation method, and kit for retinal tissue transplantation |
CN115418343A (en) * | 2022-10-28 | 2022-12-02 | 深圳市俊元生物科技有限公司 | Method for extracting pluripotent stem cells from human retinal pigment epithelial cells |
WO2024157929A1 (en) * | 2023-01-23 | 2024-08-02 | 住友ファーマ株式会社 | Method for producing retinal tissue |
CN116769713B (en) * | 2023-08-14 | 2023-10-27 | 四川大学华西医院 | Preparation method of retinal pigment epithelial cells |
CN117625536B (en) * | 2024-01-26 | 2024-04-30 | 中国人民解放军总医院第三医学中心 | Purification and culture method of human retina pigment epithelial cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105137A1 (en) * | 2007-01-18 | 2010-04-29 | Riken | Method for induction/differentiation into photoreceptor cell |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123902A1 (en) | 2004-06-18 | 2005-12-29 | Riken | Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture |
EP1947170B1 (en) * | 2005-10-21 | 2018-08-08 | Kaneka Corporation | Stem cell separating material and method of separation |
US8956866B2 (en) | 2007-04-18 | 2015-02-17 | Hadasit Medical Research Services And Development Ltd. | Retinal pigment epithelial cells differentiated from embryonic stem cells with nicotinamide and activin A |
JP5590646B2 (en) | 2009-10-08 | 2014-09-17 | 国立大学法人大阪大学 | Culture substrate for human pluripotent stem cells and use thereof |
JP2012080821A (en) * | 2010-10-12 | 2012-04-26 | Univ Of Tsukuba | Method of concentrating nucleated cell component in blood |
KR101994492B1 (en) | 2011-02-25 | 2019-06-28 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | Method of producing retinal pigment epithelial cell sheet |
JP6169972B2 (en) * | 2011-11-09 | 2017-07-26 | 株式会社カネカ | Stem cell isolation method |
US9850463B2 (en) * | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
US10519422B2 (en) | 2012-02-29 | 2019-12-31 | Riken | Method of producing human retinal pigment epithelial cells |
JP2013212345A (en) | 2012-04-03 | 2013-10-17 | Kurashiki Seni Kako Kk | Non-woven fabric for curtain and method of manufacturing the same |
KR102245015B1 (en) | 2013-10-09 | 2021-04-26 | 가부시키가이샤 헤리오스 | Method for purification of retinal pigment epithelial cells |
-
2014
- 2014-10-09 KR KR1020167012164A patent/KR102245015B1/en active IP Right Grant
- 2014-10-09 EP EP14851809.5A patent/EP3056563B1/en active Active
- 2014-10-09 CN CN201480055673.5A patent/CN105829526A/en active Pending
- 2014-10-09 JP JP2015541642A patent/JP6518879B2/en active Active
- 2014-10-09 BR BR112016007833-0A patent/BR112016007833B1/en active IP Right Grant
- 2014-10-09 SG SG11201602734SA patent/SG11201602734SA/en unknown
- 2014-10-09 EP EP14852053.9A patent/EP3056564B1/en active Active
- 2014-10-09 WO PCT/JP2014/077111 patent/WO2015053375A1/en active Application Filing
- 2014-10-09 AU AU2014332857A patent/AU2014332857B2/en active Active
- 2014-10-09 US US15/028,158 patent/US11492593B2/en active Active
- 2014-10-09 CN CN201480055588.9A patent/CN105849254A/en active Pending
- 2014-10-09 SG SG10201802879PA patent/SG10201802879PA/en unknown
- 2014-10-09 CA CA2926721A patent/CA2926721C/en active Active
- 2014-10-09 KR KR1020167012163A patent/KR102253422B1/en active IP Right Grant
- 2014-10-09 CA CA2926912A patent/CA2926912C/en active Active
- 2014-10-09 AU AU2014332856A patent/AU2014332856B2/en active Active
- 2014-10-09 US US15/028,076 patent/US20160237403A1/en active Pending
- 2014-10-09 SG SG11201602796QA patent/SG11201602796QA/en unknown
- 2014-10-09 SG SG10201802877WA patent/SG10201802877WA/en unknown
- 2014-10-09 WO PCT/JP2014/077112 patent/WO2015053376A1/en active Application Filing
- 2014-10-09 JP JP2015541641A patent/JP6518878B2/en active Active
-
2016
- 2016-05-06 ZA ZA201603051A patent/ZA201603051B/en unknown
- 2016-05-06 ZA ZA201603054A patent/ZA201603054B/en unknown
-
2019
- 2019-03-06 JP JP2019040103A patent/JP6850455B2/en active Active
- 2019-03-06 JP JP2019040104A patent/JP6850456B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105137A1 (en) * | 2007-01-18 | 2010-04-29 | Riken | Method for induction/differentiation into photoreceptor cell |
Non-Patent Citations (2)
Title |
---|
Buchholz et al., STEM CELLS 2009; 27: 2427-2434 (Year: 2009) * |
Osakada et al., In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction, Journal of Cell Science, Vol. 122, No. 17, (2009) pages 3169-3179 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10485829B2 (en) | 2009-11-17 | 2019-11-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
US11850261B2 (en) | 2009-11-17 | 2023-12-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
US11492593B2 (en) | 2013-10-09 | 2022-11-08 | Healios K.K. | Method for purification of retinal pigment epithelial cells |
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
US11649432B2 (en) | 2015-09-08 | 2023-05-16 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
US11371016B2 (en) | 2016-04-22 | 2022-06-28 | Sumitomo Pharma Co., Ltd. | Method for producing retinal tissue |
US11618883B2 (en) | 2017-03-08 | 2023-04-04 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
CN114981417A (en) * | 2019-10-30 | 2022-08-30 | 安斯泰来再生医药协会 | Method for producing retinal pigment epithelial cells |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3056563B1 (en) | Method of producing retinal pigment epithelial cell | |
US11421203B2 (en) | Method of producing human retinal pigment epithelial cells | |
JP7075556B2 (en) | Method of manufacturing nerve tissue | |
WO2017043605A1 (en) | Method for producing retinal pigment epithelial cells | |
JPWO2019017492A1 (en) | Method for maturing retinal tissue containing continuous epithelium | |
CN111607557A (en) | Method for producing ciliary marginal zone-like structure | |
JP6226349B2 (en) | Corneal endothelial cell marker | |
KR20130112862A (en) | Cardiomyocyte medium with dialyzed serum | |
KR20210121112A (en) | Dorsal-derived oligodendrocyte progenitor cells from human pluripotent stem cells | |
US20220073873A1 (en) | Method for purifying neural crest cells or corneal epithelial cells | |
CN111386338A (en) | Method for producing cell mass comprising nervous system cells or nervous tissue and non-neuroepithelial tissue, and cell mass | |
BR112016007853B1 (en) | METHOD FOR PRODUCING RETINAL PIGMENTAL EPITHELIUM CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: OSAKA UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWADA, MASANORI;TAKAHASHI, MASAYO;SEKIGUCHI, KIYOTOSHI;SIGNING DATES FROM 20160419 TO 20160428;REEL/FRAME:039066/0327 Owner name: HEALIOS K.K., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWADA, MASANORI;TAKAHASHI, MASAYO;SEKIGUCHI, KIYOTOSHI;SIGNING DATES FROM 20160419 TO 20160428;REEL/FRAME:039066/0327 Owner name: RIKEN, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAWADA, MASANORI;TAKAHASHI, MASAYO;SEKIGUCHI, KIYOTOSHI;SIGNING DATES FROM 20160419 TO 20160428;REEL/FRAME:039066/0327 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: HEALIOS K.K., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEALIOS K.K.;REEL/FRAME:063325/0645 Effective date: 20230308 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |